Caxton Associates LP Takes Position in Catalent, Inc. (NYSE:CTLT)

Caxton Associates LP acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 420,000 shares of the company’s stock, valued at approximately $18,871,000. Catalent makes up 1.0% of Caxton Associates LP’s investment portfolio, making the stock its 27th largest holding. Caxton Associates LP owned approximately 0.23% of Catalent at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Gladius Capital Management LP bought a new position in shares of Catalent in the 3rd quarter valued at about $28,000. GAMMA Investing LLC bought a new position in shares of Catalent in the 4th quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the last quarter. Rakuten Securities Inc. bought a new position in shares of Catalent in the 4th quarter valued at about $46,000. Finally, Federated Hermes Inc. bought a new position in shares of Catalent in the 4th quarter valued at about $46,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CTLT. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. StockNews.com began coverage on shares of Catalent in a research note on Thursday, June 6th. They issued a “sell” rating for the company. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $53.14.

Insider Activity

In related news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.31% of the company’s stock.

Catalent Stock Performance

NYSE CTLT traded down $0.21 on Tuesday, hitting $55.98. The stock had a trading volume of 613,854 shares, compared to its average volume of 2,284,239. The business’s fifty day moving average price is $55.73 and its 200 day moving average price is $52.28. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $60.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Sell-side analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.